Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Vanessa Rodrik-Outmezguine(Novartis (Switzerland)), Kevan M. Shokat(Howard Hughes Medical Institute), Zhan Yao(Loxo Oncology at Lilly (United States)), Sabina Cosulich(AstraZeneca (Singapore)), Helen Won(Unknown), Masanori Okaniwa(Takeda (United States)), Teresa Klinowska(AstraZeneca (Singapore)), Neal Rosen(Memorial Sloan Kettering Cancer Center), Arpitha Banaji(Memorial Sloan Kettering Cancer Center), Chris J. Novotny(Howard Hughes Medical Institute), Wai Wong(Memorial Sloan Kettering Cancer Center), Claire McWhirter(AstraZeneca (United Kingdom)), Derek Barratt(AstraZeneca (United Kingdom)), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center)
Cited by 483
Related Papers
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
|Nature|2013|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
|Nature|2011|1.4k
IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
|Science|2007|1.4k